Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Stephen M. Ansell
Observed name:
Stephen Ansell
Institution:
Mayo Clinic
Observed institution:
Mayo Clinic
ORCID:
0000-0001-7710-7293
Observed ORCID:
0000-0001-7710-7293
OpenAlex ID:
A5103081960
Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma
2011
·
Anas Younes
, Joseph M. Connors
, et al.
·
Blood
·
45
Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma
2017
·
Joseph M. Connors
, Stephen M. Ansell
, et al.
·
Blood
·
43
The Role of Radiation Therapy in the Management of Gray Zone Lymphoma
2025
·
Omran Saifi
, Scott C. Lester
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
2
Faculty Opinions recommendation of Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.
2016
·
Stephen Ansell
·
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
Show more works
View as search
Works count:
4
Citation count:
90
H-index:
2
I10-index:
2
Year
Topic
Type
